Bivasave 250Mg Inj
₹7098.8*
MRP ₹8657.07
18% off
₹7358.07*
MRP ₹8657.07
15% CB
₹1299 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Bivasave 250Mg Inj belongs to the group of medicines called blood thinners used to prevent the formation of blood clots. Blood clots are formed to stop bleeding that occurs due to tissue injury. Though blood clots are useful for stopping bleeding, they may be harmful when abnormally formed within blood vessels as they block blood vessels. Bivasave 250Mg Inj is used in combination with aspirin during Percutaneous transluminal coronary angioplasty (PTCA) and Percutaneous coronary intervention (PCI) (angioplasty procedures) in unstable angina patients to reduce the chance of blood clot formation.
Bivasave 250Mg Inj contains Bivalirudin, which works by inhibiting the production of fibrin (a protein that binds platelets together and forms a clot), preventing blood clot formation. This results in lower cardiovascular events like myocardial infarction (heart attack) or other severe chest pain-related problems.
Bivasave 250Mg Inj will be administered by your doctor. So, do not self-administer. The dose of the medicine will be decided by your doctor based on your health condition. Bivasave 250Mg Inj may cause certain side effects such as nose bleeds, skin rash, bleeding in the bowels, blood in urine, low haemoglobin, thrombocytopenia (low platelets), hypersensitivity reactions, and elevations of liver enzyme levels. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor.
Bivasave 250Mg Inj should not be used if you are allergic to it or if you ever had a brain stroke, bleeding in the brain or transient ischemic attack (stroke). Talk to your doctor before receiving Bivasave 250Mg Inj if you have/had a recent severe injury or surgery due to the risk of severe bleeding problems, have/had a heart problem, kidney disease or using any blood thinner medicine. Pregnant or breastfeeding mothers should inform the doctor before receiving this medicine. Bivasave 250Mg Inj is not recommended for children as efficacy and safety have not been established.
Bivasave 250Mg Inj belongs to the group of medicines called antithrombolytic agents (direct thrombin inhibitors) used to prevent the formation of blood clots. Bivasave 250Mg Inj works by inhibiting the production of fibrin (a protein that binds platelets together and forms a clot), preventing blood clot formation. This helps in reducing the rate of cardiovascular events such as myocardial infarction (heart attack) or stroke, especially in people who have had heart surgery, known as angioplasty.
Do not receive Bivasave 250Mg Inj if you are allergic to it or if you have a medical condition that causes bleeding from the stomach or intestine, had a transient ischemic attack (stroke) or if you are suffering from severe liver disease. Let your doctor know if you have bleeding problems, had/have a recent serious injury or surgery, kidney/liver disease, or are taking any blood thinner medicine before receiving this medicine. Consult your doctor immediately if you develop a medical condition called thrombotic thrombocytopenic purpura (blood disorder) while on treatment with Bivasave 250Mg Inj. Pregnant or breastfeeding mothers should inform their doctor before receiving this medicine. Bivasave 250Mg Inj is not recommended for children as efficacy and safety have not been established.
Drug-Drug Interactions: Bivasave 250Mg Inj may interact with pain killers (ibuprofen, celecoxib, hydrocodone, tramadol), blood thinners (clopidogrel, dalteparin, enoxaparin, rivaroxaban, prasugrel), and drug used to prevent heart attack or stroke (ticagrelor).
Drug-Food Interactions: Avoid smoking and alcohol consumption.
Drug-Disease Interactions: Inform your doctor if you have bleeding problems, coronary and cerebral vascular disease, or liver or kidney disease.
Regular blood tests are advised while taking Bivasave 250Mg Inj to monitor prothrombin, platelets and coagulation time.
Blood clot: Platelets are small cell particles that circulate in the blood. When the blood vessel is damaged or cut, the platelets clump together and lead to the formation of a clot, preventing bleeding. The formation of clots in arteries can cut off the blood supply, leading to heart attack, stroke or death. Clot formation in the arteries that supply blood to the heart may cause reduced blood flow, which could lead to unstable angina (chest pain).
Heart attack: It is a condition where a blood clot blocks a blood vessel supplying your heart, starving it of oxygen and causing chest pain and sometimes death. Quick medication is advised to reduce the risk of serious conditions due to blood clots.
Alcohol
Unsafe
Alcohol intake might increase the risk of stomach or intestine bleeding. Hence, avoid alcohol consumption while receiving Bivasave 250Mg Inj to prevent unpleasant side effects.
Pregnancy
Caution
If you are pregnant or planning pregnancy, inform your doctor before receiving Bivasave 250Mg Inj. Your doctor may prescribe this medicine if the benefits outweigh the risks.
Breast Feeding
Caution
Limited data are available on the effect of Bivasave 250Mg Inj on breastfeeding. Hence, if you are a nursing mother, inform your doctor before receiving Bivasave 250Mg Inj. Your doctor may prescribe this medicine if the benefits outweigh the risks.
Driving
Not applicable
Bivasave 250Mg Inj does not affect your ability to drive.
Liver
Caution
Bivasave 250Mg Inj should be used with caution in patients with liver impairment. Please inform your doctor if you have liver disease or any concerns regarding this.
Kidney
Caution
Bivasave 250Mg Inj should be used with caution in patients with kidney impairment. Please inform your doctor if you have kidney disease or any concerns regarding this.
Children
Unsafe
Bivasave 250Mg Inj is not recommended for use in children, as efficacy and safety have not been established.
Country of origin
Manufacturer/Marketer address
Product Substitutes